18 November 2016

Kromek Group plc
("Kromek" or the "Company")

Notice of Results

Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, will be announcing its interim results for the six months ended 31 October 2016 on Wednesday 7 December 2016.

The Company will be hosting a presentation to analysts at 12.30pm GMT, on the day, at the offices of Luther Pendragon, Second Floor, 48 Gracechurch Street, London, EC3V 0EJ.

Enquiries

Kromek Group plc	
Arnab Basu, CEO Derek Bulmer, CFO	+44 (0)1740 626 060
Cenkos Securities plc	
Bobbie Hilliam (NOMAD) Julian Morse (Sales)	+44 (0)20 7397 8900
Luther Pendragon Ltd	
Harry Chathli, Claire Norbury, Alexis Gore	+44 (0)20 7618 9100

About Kromek Group plc

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over a hundred full time employees across its global operations. Further information on Kromek Group is available at www.kromek.com.